Three Asian Stocks That Could Be Trading Below Estimated Value

As global markets navigate through economic uncertainties, Asian stock markets have shown mixed performances, with some regions experiencing growth while others face challenges. In this environment, identifying undervalued stocks becomes crucial for investors looking to capitalize on potential market inefficiencies.

Click here to see the full list of 279 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.

Let’s dive into some prime choices out of the screener.

Overview: LigaChem Biosciences Inc. is a clinical stage biopharmaceutical company focused on discovering and developing medicines for unmet medical needs, with a market cap of approximately ₩5.55 trillion.

Operations: The company’s revenue is derived from two main segments: the Pharmaceutical Business, contributing ₩20.81 billion, and New Drug Research and Development, accounting for ₩127.47 billion.

Estimated Discount To Fair Value: 24.7%

LigaChem Biosciences is currently trading 24.7% below its estimated fair value of ₩202,219.77, suggesting it may be undervalued based on cash flows despite recent financial challenges. The company reported a significant net loss for the second quarter and six months ending June 30, 2025; however, its earnings are forecast to grow at a very large rate annually over the next three years, outpacing market averages significantly.

• According our earnings growth report, there’s an indication that LigaChem Biosciences might be ready to expand.

• Click here and access our complete balance sheet health report to understand the dynamics of LigaChem Biosciences.

Overview: Akeso, Inc. is a biopharmaceutical company involved in the research, development, manufacture, and commercialization of antibody drugs globally with a market cap of HK$128.78 billion.

Operations: The company’s revenue primarily comes from the research, development, production, and sale of biopharmaceutical products, amounting to CN¥2.51 billion.